Teriflunomide Mylan Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

teriflunomide mylan

mylan pharmaceuticals limited - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - imūnsupresanti - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Teriflunomide Accord Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

teriflunomide accord

accord healthcare s.l.u. - teriflunomīds - multiplā skleroze, recidivējoši-pārskaitot - immunosuppressants, selektīvi immunosuppressants - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Hemgenix Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

hemgenix

csl behring gmbh - etranacogene dezaparvovec - hemophilia b - other hematological agents - treatment of severe and moderately severe haemophilia b (congenital factor ix deficiency) in adult patients without a history of factor ix inhibitors.

Qaialdo Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

qaialdo

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 un 5.

Suprelorin Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

suprelorin

virbac s.a. - deslorelīna acetāts - hipofīzes un hipotalāma hormoni un analogi - dogs; ferrets - lai radītu īslaicīgu neauglību veseliem, veseliem, seksuāli nobriedušiem vīriešu dzimuma suņiem un seskiem.

Vectormune ND Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

vectormune nd

ceva-phylaxia co. ltd. - šūnu saistītie dzīvot rekombinantā turcija herpes vīruss (rhvt/nd), paužot kodolsintēzes olbaltumvielu Ņūkāslas slimības vīruss d-26 lentogenic celms - immunologicals par aves, dzīvu vīrusu vakcīnas - chicken; embryonated eggs - aktīvās imunizācijas 18 dienas vecs embryonated vistu olām vai diennakti veciem cāļiem, lai samazinātu mirstību un klīniskās pazīmes, ko izraisa Ņūkāslas slimības vīrusa un, lai samazinātu mirstību, klīniskās pazīmes un bojājumi, ko izraisa marek slimības vīruss ar fenotipu "bīstami".

Tacforius Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

tacforius

teva b.v. - takrolīma monohidrāts - liver transplantation; kidney transplantation - imūnsupresanti - transplantāta atgrūšanas profilakse pieaugušo nieru vai aknu alotransplantāta recipientiem. pārstādāmā noraidījumu rezistenti pret ārstēšanu ar citām imunitāti nomācošu zālēm pieaugušiem pacientiem ārstēšana.

Hepar compositum N šķīdums injekcijām Latvia - Tiếng Latvia - Zāļu valsts aģentūra

hepar compositum n šķīdums injekcijām

biologische heilmittel heel gmbh, germany - aknu to cyanocobalaminum, divpadsmitpirkstu zarnas to thymus savas resnās zarnas to urīnpūšļa fellea to aizkuņģa dziedzeris to pieneņu officinale, lycopodium clavatum, chelidonium lielāks, skābes oroticum monohydricum, mizas pubescens, silybum marianum, histaminum, sēru, auzas sativa, nātrija diethyloxalaceticum, skābes alfa-ketoglutaricum, skābes malicum, skābes fumaricum, calcium carbonicum hahnemanni, skābes dl alfa-liponicum, cynara scolymus, veratrum album - Šķīdums injekcijām

Pegasys Liên Minh Châu Âu - Tiếng Latvia - EMA (European Medicines Agency)

pegasys

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - imunitātes stimulatori, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 un 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. attiecībā uz lēmumu uzsākt ārstēšanu pediatrijas pacientiem, skatīt 4. 2, 4. 4 un 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 un 5. hepatīta c vīrusa (hcv) genotipa konkrētu darbību, skatīt 4. 2 un 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. pieņemot lēmumu uzsākt ārstēšanu bērnības, tas ir svarīgi apsvērt, augšanas inhibēšanas saistītas ar kombinēto terapiju,. atgriezeniskumu augšanas inhibēšanas ir neskaidra. lēmumu, lai ārstētu būtu jāpieņem katrā gadījumā atsevišķi (skatīt 4. iedaļu.